Emerging evidence suggests that the airway microbiota plays an important role in viral bronchiolitis pathobiology. However, little is known about the combined role of airway microbiota and CCL5 in infants with bronchiolitis. In this multicenter prospective cohort study of 1005 infants (age <1 year) hospitalized for bronchiolitis during 2011-2014, we observed statistically significant interactions between nasopharyngeal airway CCL5 levels and microbiota profiles with regard to the risk of both intensive care use (P interaction =.02) and hospital length-of-stay ≥3 days (P interaction =.03). Among infants with lower CCL5 levels, the Haemophilus-dominant microbiota profile was associated with a higher risk of intensive care use (OR, 3.20; 95%CI, 1.18-8.68; P=.02) and hospital length-of-stay ≥3 days (OR, 4.14; 95%CI, 2.08-8.24; P<.001) compared to the Moraxella-dominant profile. Conversely, among those with higher CCL5 levels, there were no significant associations between the microbiota profiles and these severity outcomes (all P≥.10). Additionally, we recently identified,
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Abstract
Emerging evidence suggests that the airway microbiota plays an important role in viral bronchiolitis pathobiology. However, little is known about the combined role of airway microbiota and CCL5 in infants with bronchiolitis. In this multicenter prospective cohort study of 1005 infants (age <1 year) hospitalized for bronchiolitis during 2011-2014, we observed statistically significant interactions between nasopharyngeal airway CCL5 levels and microbiota profiles with regard to the risk of both intensive care use (P interaction =.02) and hospital length-of-stay ≥3 days (P interaction =.03). Among infants with lower CCL5 levels, the Haemophilus-dominant microbiota profile was associated with a higher risk of intensive care use (OR, 3.20; 95%CI, 1.18-8.68; P=.02) and hospital length-of-stay ≥3 days (OR, 4.14; 95%CI, 2.08-8.24; P<.001) compared to the Moraxella-dominant profile. Conversely, among those with higher CCL5 levels, there were no significant associations between the microbiota profiles and these severity outcomes (all P≥.10).
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| INTRODUCTION
Bronchiolitis is the most common lower respiratory infection in young children, accounting for 18% of infant hospitalizations in the USA. 1 While bronchiolitis is traditionally viewed as viral-induced inflammation of bronchioles, recent studies suggest the presence of a complex interplay among the virus pathogens, airway microbiome, and host immune response systems. [2] [3] [4] [5] Of the various components of the host immune systems, CCL5 is a b-chemokine chemoattractant that, via virus (eg, respiratory syncytial virus [RSV]) 6 -and bacteria-induced activation of Toll-like receptors in airway epithelia, recruits a variety of innate and adaptive immune cells. 7 Studies have also shown that specific gut microbiota induce CCL5-driven inflammation in animal models. 8, 9 Additionally, we recently identified, among infants hospitalized for bronchiolitis ("severe bronchiolitis"), that those with specific nasopharyngeal airway microbiota (Haemophilus-dominant profile) had the highest disease severity, 4 and that this association was observed only in those with low circulating cathelicidin levels. 5 However, interrelations between the microbiota and host immune response (eg, CCL5) within the airway niche were not investigated. In the current analysis, we studied the same cohort of infants with severe bronchiolitis to determine the interaction between the nasopharyngeal microbiota and CCL5 with regard to the disease severity.
| ME TH ODS
We analyzed data from a multicenter prospective cohort study of infants with severe bronchiolitis. Details of the study design, setting, population, data collection and testing, and analysis may be found in the (Data S1 The institutional review board of every participating hospital approved the study. Written informed consent was obtained from the infant's parent or guardian.
In addition to the collection of phenotypic data through structured interview and medical record review, investigators also collected nasopharyngeal aspirates within 24 hours of hospitalization using a standardized protocol. Nasopharyngeal CCL5 concentration was quantified using an enzyme-linked immunosorbent assay. Composition of nasopharyngeal microbiota was characterized by sequencing the bacterial 16S rRNA gene V4 region on the Illumina MiSeq platform. The details of these testing may be found in Data S1. As previously described, 4 using an unbiased clustering approach (partitioning around medoids method), we derived four distinct nasopharyngeal microbiota profiles:
Moraxella-dominant, Streptococcus-dominant, and mixed profiles ( Figure S1 ).
For the present analysis, we used the median level to divide the nasopharyngeal CCL5 levels into two groups: low CCL5 (≤42.0 pg/mL) and high CCL5 (>42.0 pg/mL). The primary outcome was intensive care use (defined as admission to intensive care unit and/or use of mechanical ventilation); the secondary outcome was hospital lengthof-stay of ≥3 days. 4 To examine the difference in microbiota- (Table S2) , the infants with lower CCL5 levels were younger, more likely to have received antibiotics during their prehospitalization visit, and had lower RSV genomic loads (all P<.05) compared to those with higher CCL5 levels. There were no significant between-group differences in the detected viruses, serum LL-37 levels, nasopharyngeal microbiota profiles (Table S2) , or relative abundance of major bacteria genera (all P≥.10; Table S3 ). Additionally, there was no significant correlation between the nasopharyngeal CCL5 and serum LL-37 levels (P=.76; Figure S2 ).
By contrast, we found statistically significant interactions between nasopharyngeal CCL5 status and microbiota profiles with regard to the risk of both intensive care use (P interaction =.02) and hos- Likewise, among infants with lower CCL5 levels, the Haemophilus-dominant profile was associated with a higher risk of hospital length-of-stay ≥3 days (adjusted OR, 4.14; 95%CI, 2.08-8.24; P<.001) compared to the Moraxella-dominant profile (Figure 1 ).
By contrast, among those with higher CCL5 levels, there were no significant associations (all P≥.10).
| DISCUSSION
In this multicenter cohort study of 1005 infants with severe bronchiolitis, we found a statistically significant interaction between nasopharyngeal airway CCL5 and microbiota profiles with regard to the disease severity. Specifically, among infants who had low CCL5 levels, the Haemophilus-dominant microbiota profile was associated with a higher risk of intensive care use and longer hospital length-of-stay. These observed interactions were independent from viral pathogens and circulating cathelicidin levels. By contrast, in those with high CCL5 levels, there
were no associations between the microbiota profiles and disease severity.
Emerging evidence suggests that a complex interplay among the respiratory viruses, airway microbiome, and host immune response Haemophilus-dominant microbiota had upregulation of the genes linked to Toll-like receptors and macrophage activation in the whole blood. 2 The present study corroborates these prior reports and extends them by demonstrating, for the first time, the interaction between the microbiota and host immune response (particularly CCL5) within the airway niche with regard to the respiratory infection severity.
The nature of the observed microbiota-CCL5-severity interrelation warrants elucidation. It is possible that a specific function (not structure) of the airway microbiota, through altering the expression of CCL5 locally, influences bronchiolitis severity. Indeed, Elinav et al., in mouse models, reported that an aberrant gut microbiota changes local epithelial induction of CCL5 transcription as a downstream mechanism and leads to an exaggerated inflammatory response locally (ie, exacerbation of colitis). 8 Another mechanism is that airway CCL5, by recruiting a variety of immune cells, modifies the airway microbiota and jointly contributes to the bronchiolitis pathobiology (and host resilience). Furthermore, these mechanisms are not mutually exclusive.
Despite this complexity, the identification of significant interactions between the microbiota and CCL5 within the airway of infants with bronchiolitis is an important finding. Our data should facilitate mechanistic investigations into the complex cross talk among the respiratory viruses, microbiota, and host immune systems, and help to define their integrated role in bronchiolitis pathobiology.
This study has several potential limitations. First, our data are based on the nasopharyngeal microbiota and CCL5 level while bronchiolitis involves inflammation of the lower airways. Yet, lower airway sampling in infants is technically and ethically challenging.
Furthermore, the literature has demonstrated that there are significant correlations between upper and lower airway inflammatory mediators, including CCL5, 11 and that upper airway microbiota is reliable representation of bronchoalveolar lavage microbiota in young children. 12 Second, the current analytic design precluded investigations into the relation between the airway microbiome succession and respiratory health in children (eg, incident asthma). To address this question, the MARC-35 cohort is currently being followed up to 6 years of age, with airway sampling at multiple time-points. Third, despite a rigorous adjustment for confounding factors (eg, age, prior use of systemic antibiotics), the observed associations might be confounded by unmeasured factors. Fourth, our study did not include the data of a "control" group (eg, asymptomatic infants). Nevertheless, the study aim is not to evaluate the role of airway microbiota and CCL5 on the development of bronchiolitis but to investigate their integrated contributions to the disease severity among infants with bronchiolitis. Lastly, even with our racially/ethnically and geographically diverse US sample, the inferences might not be generalizable beyond infants who had severe bronchiolitis. Still, our data remain directly relevant for 130 000 hospitalized US children each year. 1 In summary, on the basis of the multicenter cohort of 1005 infants hospitalized for bronchiolitis, we identified a statistically significant interaction between the nasopharyngeal microbiota profiles and CCL5 status with regard to the risk of intensive care use and longer hospital length-of-stay. These findings indicate that the microbiota-severity associations differ by airway CCL5 levels.
Although the clinical relevance of these findings is not yet determined, our data should underscore the importance of understanding the integrated contributions of respiratory viruses, airway microbiome, and immune systems to the pathobiology of bronchiolitis.
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